vTv Therapeutics Inc. (VTVT) shareholders
Close on Nov 17, 2026Market cap $68.37MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| The ROP Revocable Trust dated 1/9/2018 Joint filing with MacAndrews & Forbes Incorporated (47.80%), MacAndrews & Forbes LLC (21.40%) and 5 more | 1,535,685 | 50.30% | 13D (active) amendment | Feb 27, 2024 |
| Srinivas Akkaraju Joint filing with Samsara BioCapital, L.P. (6.20%), Samsara BioCapital GP, LLC (6.20%) | 403,942 | 9.90% | 13D (active) amendment | Dec 8, 2025 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (8.40%), Invus Public Equities Advisors, LLC (8.40%) and 2 more | 393,098 | 9.40% | 13G (passive) amendment | Sep 30, 2025 |
| Israel A. Englander Joint filing with Millennium Management LLC (8.70%), Millennium Group Management LLC (8.70%) and 1 more | 342,481 | 8.70% | 13G (passive) amendment | Sep 30, 2026 |
| Ortav Yehudai Joint filing with Trails Edge Capital Partners, LP (9.90%), Trails Edge Biotechnology Master Fund, LP (9.90%) | 340,536 | 9.90% | 13G (passive) | Aug 29, 2025 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.70%), Israel A. Englander (5.70%) and 1 more | 225,073 | 5.70% | 13G (passive) amendment | Apr 13, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.00%), Israel A. Englander (5.00%) | 198,237 | 5.00% | 13G (passive) | Mar 24, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (7.32%) | 178,200 | 7.32% | 13G (passive) | Nov 12, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VTVT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 298,496 | 7.55% | $11.24M | – | 0.92% |
| Millennium Management LLC | 269,874 | 6.83% | $10.16M | +63,586 | 0.00% |
| FMR LLC | 260,391 | 6.59% | $9.80M | – | 0.00% |
| Siren, L.L.C. | 163,000 | 4.12% | $6.14M | – | 0.12% |
| Baker Bros. Advisors LP | 148,314 | 3.75% | $5.58M | – | 0.03% |
| Vanguard Capital Management LLC | 94,463 | 2.39% | $3.56M | −14,459 | 0.00% |
| Trails Edge Capital Partners, LP | 85,192 | 2.15% | $3.21M | −54,386 | 0.51% |
| Aisling Capital Management LP | 50,000 | 1.26% | $1.88M | New | 0.40% |
| Marshall Wace, Llp | 39,560 | 1.00% | $1.49M | +26,171 | 0.00% |
| Geode Capital Management, LLC | 32,470 | 0.82% | $1.22M | −416 | 0.00% |
| Renaissance Technologies LLC | 17,454 | 0.44% | $657.14K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 16,239 | 0.41% | $611.40K | +113 | 0.00% |
| BlackRock, Inc. | 14,731 | 0.37% | $554.62K | +2,129 | 0.00% |
| Jane Street Group, LLC | 13,703 | 0.35% | $515.92K | New | 0.00% |
| State Street Corp | 12,266 | 0.31% | $461.82K | +1,600 | 0.00% |
| Two Sigma Investments, LP | 11,486 | 0.29% | $432.45K | New | 0.00% |
| Verdad Advisers, LP | 8,996 | 0.23% | $338.70K | New | 0.32% |
| Integrated Quantitative Investments LLC | 8,210 | 0.21% | $309.11K | New | 0.05% |
| Susquehanna International Group, Llp | 8,023 | 0.20% | $302.07K | New | 0.00% |
| Quadrature Capital Ltd | 6,305 | 0.16% | $237.38K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 2M | 40.6% | 17 / 6 | 8 / 6 | 0M | 0M |
| Q1 2026 | 35 | 1M | 37.6% | 12 / 7 | 4 / 3 | 0M | 0M |
| Q4 2025 | 27 | 1M | 32.5% | 7 / 8 | 3 / 3 | 0M | 0M |
| Q3 2025 | 23 | 1M | 25.0% | 3 / 8 | 3 / 1 | 0M | 0M |
| Q2 2025 | 21 | 1M | 14.8% | 3 / 6 | 3 / 3 | 0M | 0M |
| Q1 2025 | 21 | 1M | 14.5% | 5 / 2 | 6 / 1 | 0M | 0M |
| Q4 2024 | 17 | 1M | 13.9% | 1 / 5 | 1 / 3 | 0M | 0M |
| Q3 2024 | 20 | 1M | 13.7% | 6 / 2 | 1 / 4 | 0M | 0M |
| Q2 2024 | 19 | 0M | 8.8% | 5 / 3 | 2 / 5 | 0M | 0M |
| Q1 2024 | 19 | 0M | 8.5% | 6 / 6 | 4 / 1 | 0M | 0M |
| Q4 2023 | 14 | 0M | 1.8% | 13 / 0 | 0 / 0 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
13 funds held VTVT in Q2 2026, 26% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VTVT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 260,391 | 6.59% | $8.68M | 0.16% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 60,763 | 1.54% | $2.29M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 31,402 | 0.79% | $1.18M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 14,732 | 0.37% | $491.31K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 7,234 | 0.18% | $272.36K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 4,779 | 0.12% | $159.38K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,193 | 0.11% | $139.84K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,524 | 0.06% | $84.18K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 1,523 | 0.04% | $57.34K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 775 | 0.02% | $29.18K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 486 | 0.01% | $18.30K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 236 | 0.01% | $7.63K | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 88 | 0.00% | $3.31K | 0.00% | Jun 30, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 11 | 0.00% | $356 | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul J. Sekhri | Pres, CEO and Exec Chairperson, Director | 392,212 | 9.92% | Feb 18, 2026 |
| Michael Stephen Tung | EVP & CFO | – | – | Feb 18, 2026 |
| Barry K. Brown | Chief Accounting Officer | 4 | 0.00% | Apr 11, 2025 |
| Felix Baker | Director | – | – | Jun 29, 2026 |
| Brothers Life Sciences LP Baker | Director | – | – | Jun 29, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | – | – | Jun 29, 2026 |
| 667, L.P. | Director | 89,254 | 2.26% | Jun 29, 2026 |
| Daniel K. Spiegelman | Director | – | – | Jun 29, 2026 |
| Fahed Al-Marzooqi | Director | – | – | Jun 29, 2026 |
| Srinivas Akkaraju | Director | 312,784 | 7.91% | Jun 29, 2026 |
| Bros. Advisors Lp Baker | Director | 142,135 | 3.59% | Jun 29, 2026 |
| Julian Baker | Director | 12,368 | 0.31% | Jun 29, 2026 |
| Anne M. Phillips | Director | – | – | Jun 29, 2026 |
| Samsara BioCapital, L.P. | 10% owner | 206,784 | 5.23% | Dec 6, 2024 |
| Samsara BioCapital GP, LLC | 10% owner | – | – | Dec 6, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Srinivas Akkaraju Director | Sep 22, 2025 | Award | +106,000 | $15.27 | $1.62M | 106,000 |
| Julian Baker Director | Sep 3, 2025 | Award | +4,308 | – | – | 12,368 |
| Julian Baker Director | Sep 3, 2025 | Award | +46,692 | – | – | 135,946 |
| Paul J. Sekhri Pres, CEO and Exec Chairperson, Director | Nov 18, 2024 | Buy | +1,844 | $16.96 | $31.27K | 5,000 |
| Paul J. Sekhri Pres, CEO and Exec Chairperson, Director | Nov 15, 2024 | Buy | +1,378 | $16.35 | $22.53K | 1,378 |
| Paul J. Sekhri Pres, CEO and Exec Chairperson, Director | Nov 15, 2024 | Buy | +1,778 | $16.88 | $30.01K | 3,156 |
| Samsara BioCapital, L.P. 10% owner | Mar 5, 2024 | Other | −58,836 | – | – | 206,784 |
| Srinivas Akkaraju Director, 10% owner | Mar 5, 2024 | Returned to company | −58,836 | – | – | 206,784 |
| 667, L.P. Director | Mar 5, 2024 | Returned to company | −52,881 | – | – | 89,254 |
| 667, L.P. Director | Mar 5, 2024 | Returned to company | −4,776 | – | – | 8,060 |
| Srinivas Akkaraju Director, 10% owner | Feb 27, 2024 | Award | +224,732 | $11.81 | $2.65M | 265,620 |
| John A. Fry Director | Nov 29, 2022 | Buy | +40,461 | $0.83 | $33.58K | 61,000 |
| John A. Fry Director | Nov 28, 2022 | Buy | +20,539 | $0.83 | $17.05K | 20,539 |
| Ronald O. Perelman 10% owner | Dec 20, 2021 | Sale | −87,000 | $1.15 | $100.05K | 36,519,212 |
| Hersh Kozlov Director | Feb 26, 2021 | Buy | +10,000 | $2.74 | $27.40K | 25,000 |
| Rich S. Nelson Director | Feb 26, 2021 | Buy | +10,000 | $2.86 | $28.60K | 10,000 |
| Rich S. Nelson Director | Feb 26, 2021 | Buy | +50,000 | $2.86 | $143.00K | 50,000 |
| Ronald O. Perelman 10% owner | Dec 17, 2020 | Buy | +625,000 | $1.60 | $1.00M | 36,606,212 |
| Ronald O. Perelman 10% owner | Dec 10, 2020 | Buy | +625,000 | $1.60 | $1.00M | 35,981,212 |
| Ronald O. Perelman 10% owner | Nov 24, 2020 | Buy | +625,000 | $1.60 | $1.00M | 35,356,212 |
| Hersh Kozlov Director | May 15, 2020 | Buy | +10,000 | $3.00 | $30.00K | 15,000 |
| Ronald O. Perelman 10% owner | May 12, 2020 | Buy | +625,000 | $1.60 | $1.00M | 34,731,212 |
| Jeffrey B. Kindler Director | Mar 10, 2020 | Option exercise | +11,667 | – | – | 35,000 |
| Ronald O. Perelman 10% owner | Feb 25, 2020 | Buy | +1,250,000 | $1.60 | $2.00M | 34,106,212 |
| Ronald O. Perelman 10% owner | Jan 28, 2020 | Buy | +1,250,000 | $1.60 | $2.00M | 32,856,212 |
| Ronald O. Perelman 10% owner | Jan 7, 2020 | Buy | +1,250,000 | $1.60 | $2.00M | 31,606,212 |
| Ronald O. Perelman 10% owner | Dec 18, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 30,356,212 |
| Ronald O. Perelman 10% owner | Nov 26, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 28,986,349 |
| Ronald O. Perelman 10% owner | Nov 12, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 27,616,486 |
| Ronald O. Perelman 10% owner | Oct 24, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 26,246,623 |
| Ronald O. Perelman 10% owner | Sep 27, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 24,876,760 |
| Ronald O. Perelman 10% owner | Sep 18, 2019 | Buy | +606,061 | $1.65 | $1.00M | 23,506,897 |
| Hersh Kozlov Director | Sep 13, 2019 | Buy | +5,000 | $1.65 | $8.25K | 5,000 |
| Ronald O. Perelman 10% owner | Sep 11, 2019 | Buy | +606,061 | $1.65 | $1.00M | 22,900,836 |
| Ronald O. Perelman 10% owner | Sep 4, 2019 | Buy | +606,061 | $1.65 | $1.00M | 22,294,775 |
| Ronald O. Perelman 10% owner | Aug 22, 2019 | Buy | +50,000 | $1.38 | $69.00K | 21,688,714 |
| Ronald O. Perelman 10% owner | Aug 19, 2019 | Buy | +150,000 | $1.31 | $196.50K | 21,638,714 |
| Ronald O. Perelman 10% owner | Aug 6, 2019 | Buy | +1,212,121 | $1.65 | $2.00M | 21,488,714 |
| Ronald O. Perelman 10% owner | Jul 9, 2019 | Buy | +1,212,121 | $1.65 | $2.00M | 20,276,593 |
| Ronald O. Perelman 10% owner | Jun 25, 2019 | Buy | +1,212,121 | $1.65 | $2.00M | 19,064,472 |
| Ronald O. Perelman 10% owner | May 15, 2019 | Buy | +1,358,698 | $1.84 | $2.50M | 17,852,351 |
| Jeffrey B. Kindler Executive Chairman, Director | Mar 10, 2019 | Option exercise | +11,666 | – | – | 23,333 |
| Ronald O. Perelman 10% owner | Feb 28, 2019 | Buy | +815,217 | $1.84 | $1.50M | 16,493,653 |
| Ronald O. Perelman 10% owner | Feb 14, 2019 | Buy | +815,217 | $1.84 | $1.50M | 15,678,436 |
| Ronald O. Perelman 10% owner | Jan 29, 2019 | Buy | +815,217 | $1.84 | $1.50M | 14,863,219 |
| Ronald O. Perelman 10% owner | Jan 16, 2019 | Buy | +815,217 | $1.84 | $1.50M | 14,048,002 |
| Ronald O. Perelman 10% owner | Dec 27, 2018 | Buy | +815,217 | $1.84 | $1.50M | 13,232,785 |
| Ronald O. Perelman 10% owner | Nov 29, 2018 | Buy | +1,879,700 | $1.33 | $2.50M | 12,417,568 |
| Ronald O. Perelman 10% owner | Nov 6, 2018 | Buy | +1,879,699 | $1.33 | $2.50M | 10,537,868 |
| Ronald O. Perelman 10% owner | Sep 27, 2018 | Buy | +1,879,699 | $1.33 | $2.50M | 8,658,169 |
| Ronald O. Perelman 10% owner | Sep 6, 2018 | Buy | +1,879,699 | $1.33 | $2.50M | 6,778,470 |
| Paul G. Savas Director | Sep 6, 2018 | Buy | +5,000 | $1.00 | $5.00K | 91,781 |
| Ronald O. Perelman 10% owner | Aug 10, 2018 | Buy | +570,777 | $4.38 | $2.50M | 4,898,771 |
| Ronald O. Perelman 10% owner | Jul 6, 2018 | Buy | +570,776 | $4.38 | $2.50M | 4,327,994 |
| Ronald O. Perelman 10% owner | Jun 18, 2018 | Buy | +570,776 | $4.38 | $2.50M | 3,757,218 |
| Ronald O. Perelman 10% owner | May 24, 2018 | Buy | +570,776 | $4.38 | $2.50M | 3,186,442 |
| Jeffrey B. Kindler Executive Chairman, Director | Mar 10, 2018 | Option exercise | +11,667 | – | – | 11,667 |
| Ronald O. Perelman 10% owner | Dec 26, 2017 | Buy | +50,000 | $4.03 | $201.50K | 2,615,666 |
| Paul G. Savas Director | Dec 7, 2017 | Buy | +5,000 | $4.57 | $22.85K | 86,781 |
| Paul G. Savas Director | Dec 6, 2017 | Buy | +10,000 | $4.55 | $45.50K | 81,781 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of vTv Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,412 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Steven L. Tuch Officer | May 1, 2025 | 1,258 | $25.16K | May 1, 2025 | Exercised Shares |
| Steven L. Tuch Officer | Apr 29, 2025 | 1,000 | $21.50K | Apr 29, 2025 | Exercised Shares |
| Steven L. Tuch Officer | Apr 24, 2025 | 1,000 | $21.50K | Apr 24, 2025 | Exercised Shares |
See a number that looks wrong?